Biotech | March 01, 2022
AstraZeneca and Neurimmune enter licencing agreement to develop and commercialise NI006
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
New inhalers would have near-zero Global Warming Potential propellant
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
Subscribe To Our Newsletter & Stay Updated
